Natera Reports Fourth Quarter and Year 2020 Financial Results
News provided by
Share this article
Share this article
SAN CARLOS, Calif., Feb. 25, 2021 /PRNewswire/ Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided an update on recent business progress.
Recent Accomplishments & Highlights
Generated total revenues of $112.4 million in the fourth quarter of 2020 compared to $83.2 million in the fourth quarter of 2019, an increase of 35.1%. Product revenues grew 43% over the same period.
Generated total revenues of $391 million in the year 2020 compared to $302.3 million in the year 2019, an increase of 29.3%, exceeding the 2020 revenue guidance range previously provided.
Have a case of Covid variant? No one is going to tell you msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
Have a case of a COVID variant? No one is going to tell you
The problem is that the tests in question for detecting variants have not been approved as a diagnostic tool either by the Food and Drug Administration or under federal rules governing university labs ― meaning that the testing being used right now for genomic sequencing is being done as high-level lab research with no communication back to patients and their doctors.
Written By:
Christina Jewett, JoNel Aleccia and Rachana Pradhan / Kaiser Health News | 10:56 am, Feb. 25, 2021 ×
A child places his testing swab in the vial for pool testing to prevent the spread of the coronavirus disease (COVID-19) in the classroom Jan. 28, 2021 at South Boston Catholic Academy in Boston. REUTERS/Allison Dinner
Have a case of a COVID variant? No one is going to tell you superiortelegram.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from superiortelegram.com Daily Mail and Mail on Sunday newspapers.
Canton Daily Ledger
PEKIN Reditus Laboratories announced it has received accreditation from the College of American Pathologists (CAP). The application for CAP is a lengthy and time-consuming process that Reditus knew it could achieve under the direction of Dr. Joshua Geltz.
The CAP’s Laboratory Accreditation Program is recognized as the champion of laboratory excellence. The rigorous accreditation process which laboratories undergo to meet these requirements commonly exceed the standards of the Clinical Laboratory Improvement Amendments (CLIA), the U.S. Food and Drug Administration and the Occupational Safety and Health Administration. CAP’s areas of measure include laboratory safety, procedures, training, documentation, and personnel qualifications. The accreditation process also included an on-site visit of an inspection team of practicing lab professionals. Reditus Laboratories was able to meet these requirements with a perfect score in all areas assessed Jan. 28.